interval (CI) 1.2–35; $p=0.026$) and presence of nodular conglomerates (OR 4.8; CI 1.4–16.1; $p=0.01$) were the key predictors of ground glass opacity (GGO) CT phenomenon. In 90% of patients EN did not relapse, and articular syndrome almost completely regressed during 1 year follow-up.

Conclusions: Patients with an acute form of sarcoidosis require coordinated action of different medical specialties, including rheumatologists, to determine the scope of further examination and adequate therapeutic regimen.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.2094

THU0634 RISK OF SUDDEN CARDIAC DEATH IN PATIENTS WITH SARCOIDOSIS: A POPULATION-BASED RETROSPECTIVE COHORT STUDY

A.A. Chahal¹, P.A. Brady¹, C.S. Crowson², V.K. Somers¹, E.L. Matteson², P. Ungprasert³. ¹Cardiovascular Diseases; ²Rheumatology, Mayo Clinic, Rochester, USA; ³Research and development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Background: Sarcoidosis is an inflammatory, non-caseating, granulomatous disorder of unknown etiology which can affect any body system including the heart and can be associated with increased risk of cardiovascular disease including sudden cardiac death (SCD). However, the risk and incidence of SCD are unknown.

Objectives: We sought to determine whether the risk of SCD in patients with sarcoidosis is higher than in the general population.

Methods: A population-based cohort of 345 incident cases of sarcoidosis (50% female; 90% Caucasian, 5% African-American; mean age 45.6 years) among Olmsted County, Minnesota residents in 1976–2013 was identified from a comprehensive medical record-linkage system. Medical records of those cases were individually reviewed to confirm the diagnosis of sarcoidosis which required physician diagnosis supported by histopathology, compatible clinical presentation and exclusion of other granulomatous diseases. A total of 345 sex and age-matched comparators (50% female; 95% Caucasian, 1% African-American; mean age 45.4 years) were also identified from the same underlying population. Mortality, including time, place and cause of death of cases and comparators were individually reviewed for SCD events. SCD incidence rates are reported per 1 00 000 person-years and Cox proportional hazards models were used for comparisons between groups.

Results: The median length of follow-up was 12.9 (6.0–23.4) years and 15.8 (6.8–25.5) for cases and comparators, respectively. Of the 58 deaths in patients with sarcoidosis, 10 were due to definite/probable SCD, versus 57 all-cause and 9 definite/probable SCDs in comparators. Incidence rate of SCD in sarcoidosis was 192 per 1 00 000 person-years (PY) (95% confidence interval (CI), 92–352) versus 155 per 100,000 PY (95% CI, 71–294) in comparators, corresponding to the hazard ratio of 1.28 (95% CI, 0.52–3.17, $p=0.59$). Analysis by time of SCD, sex, age, calendar year of incidence/index date also did not reveal a significantly different rate of SCD between the 2 groups as demonstrated in table 1.

Category	Number of deaths in sarcoidosis/non-sarcoidosis	Rate per 100,000 PY in sarcoidosis (95% CI)	Rate per 100,000 PY in non-sarcoidosis (95% CI)	Hazard Ratio (95% CI)	p-value
SCD at night (22:00–06:00)	3/1	57 (12–168)	17 (0.4–95)	3.76 (0.39–36.47)	0.25
SCD at day	6/6	115 (42–250)	103 (38–224)	1.16 (0.37–3.60)	0.80
SCD an unknown time	1/2	NA	NA	NA	
Females	6/6	217 (79–471)	205 (75–447)	1.12 (0.37–3.47)	0.85
Males	4/3	163 (44–418)	103 (21–302)	1.49 (0.33–6.69)	0.60
Age: 18–39 years	0/0	0	0	NA	
Age: 40–59 years	2/0	76 (9–275)	0	NA	
Age: 60+ years	8/9	450 (194–886)	470 (215–895)	NA	
1976–1994	3/3	259 (54–756)	228 (47–666)	NA	

1995–2004	1/2	62 (2–345)	110 (13–397)	NA
2005+	6/4	244 (90–532)	149 (41–382)	NA

Conclusions: In this first ever population-based evaluation of SCD in sarcoidosis, patients are not at increased risk for SCD (all sub-types). These findings may reflect actual risk, but estimates may be affected by low statistical power. Future studies may further elucidate the risk and nature of cardiac death among patients with sarcoidosis.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5530

THU0635 PREGNANCY OUTCOMES IN MIXED CONNECTIVE TISSUE DISEASE: RESULTS FROM A MULTICENTRE COHORT STUDY

M. Radin¹, K. Schreiber², M. Cuadrado², I. Cecchi¹, A. Laura³, F. Franceschini³, T. Caleiro⁴, E. Gibbone⁵, M. Khamashta⁶, J. Buyon⁷, P. Izmirly⁷, M. Aguirre Zamorano⁸, D. Roccatoello¹, L. Marozio⁵, S. Sciascia¹. ¹Università di Torino, Turin, Italy; ²Guy's and St Thomas' Hospital, London, UK; ³Università di Brescia, Brescia, Italy; ⁴Universidade de Sao Paulo, Sao Paulo, Brazil; ⁵Sant'Anna University Hospital, Turin, Italy; ⁶Dubai Hospital, Dubai, United Arab Emirates; ⁷New York University School of Medicine, New York, USA; ⁸University Hospital Reina Sofia, Cordoba, Spain

Background: Mixed connective tissue disease (MCTD) is characterised by signs and symptoms of a combination of disorders, primarily systemic lupus erythematosus (SLE), scleroderma and polymyositis and is characterised by the presence of high titre antibodies to U1-ribonucleoprotein (RNP).

When planning a pregnancy in patients with connective tissue diseases, ENA profiling is suggested but generally refers to testing for maternal antibodies specifically to components of the SSA/Ro-SSB/La ribonucleoprotein complex since these have been associated with foetal cardiac conduction abnormalities and neonatal skin rashes. Nevertheless, little is known about the maternal and foetal pregnancy outcomes in women with the presence of anti-U1RNP antibodies absent reactivity to SSA/Ro-SSB/La.

Objectives: We aimed to investigate foetal and maternal pregnancy outcomes from a large multicentre cohort of MCTD women.

Methods: Data was retrospectively collected from S. Giovanni Bosco Hospital and Sant' Anna University Hospital, Turin, Italy, the Lupus Unit, Department of Rheumatology at St Thomas' Hospital, London, UK, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Hospital Reina Sofia de Córdoba, Spain, ASST Spedali Civili di Brescia, Brescia, Italy.

Inclusion criteria included: Women ever pregnant who fulfilled the established criteria of MCTD with confirmed anti-U1RNP positivity.

Results: This multicentre retrospective cohort study describes the foetal and maternal outcomes of 203 pregnancies in 94 consecutive women ever pregnant (mean age at data collection 45.1 years old, S.D. 10.9; mean disease duration at data collection 12.9 years, S.D. 8.5). Demographic, clinical and laboratory characteristics are summarised in table 1. Of the 203 pregnancies analysed the foetal outcomes were as follows: 146 (71.9%) resulted in live births, 38 (18.7%) in miscarriages, 18 (8.9%) in stillbirths (after 20 weeks gestation) and eleven (5.4%) cases showed intrauterine growth restriction (IUGR). Maternal pregnancy outcomes were as follows: eight (3.9%) cases developed pre-eclampsia, two (0.9%) cases developed eclampsia, 31 (15.3%) women developed gestational hypertension and three (1.5%) cases were diagnosed with gestational diabetes. Moreover, we report a case of complete congenital heart block (0.45%) and a case of skin rash in consecutive offspring born to a mother with anti U1RNP antibodies in the absence of anti-Ro/SSA-SSB/La antibodies.

Patient Characteristics	All (94)	%
Age at data collection, mean (S.D.), years	45.1 (10.9)	
Ethnicity		
Caucasian, n	64	68.1
Black, n	9	9.6
Asian, n	4	4.3
Other, n	17	18.1
Diagnosis		
MCTD, n	94	100
Disease duration at data collection, mean (S.D.), years	12.9 (8.5)	
MCTD and aPL, n	13	13.8
MCTD and APS, n	6	6.4
Clinical manifestations		
Hematological, n	36	38.3
Skin, n	57	60.6
Joints, n	65	69.1
Cardiac, n	10	10.6
Renal, n	9	9.6
Muscular, n	31	33
Raynaud's, n	66	70.2
Pulmonary, n	27	28.7
Neurological, n	6	6.4
Cardiovascular risk factors		
History of smoking, n	10	10.6
Arterial Hypertension, n	13	13.8
Hyperlipidemia, n	11	11.7
Diabetes, n	2	2.1
Laboratory testing		
Hypocomplementemia (C3), n	28	29.8
Hypocomplementemia (C4), n	25	26.6
anti-dsDNA positive, n	12	12.8
Hypergammaglobulinemia, n	47	50

Conclusions: The observed live-birth-rate was as high as 72%, with poorer foetal outcomes observed in MCTD women with antiphospholipid antibodies and

pulmonary or muscular involvement. While the true frequency of heart block associated with anti-U1RNP remains to be determined, this study raises the consideration of echocardiographic surveillance in this setting. Women with MCTD should receive a specific counselling when planning a pregnancy, as it is currently done in women with SLE.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5188

THU0636 CANAKINUMAB TREATMENT IN ADULT-ONSET STILL'S DISEASE: CASE SERIES

S. Ugurlu¹, G. Guzelant¹, B. Yurtas¹, B. Ergezen¹, E. Dalkilic², T. Kasifoglu³, B. Yagiz², H. Ozdogan¹. ¹Division of Rheumatology, Department of Internal Medicine, Istanbul University, Cerrahpaşa Medical Faculty, Istanbul; ²Division of Rheumatology, Department of Internal Medicine, Uludağ University, Medical Faculty, Bursa; ³Division of Rheumatology, Department of Internal Medicine, Osmangazi University, Medical Faculty, Eskişehir, Turkey

Background: In Adult-onset Still's disease (AOSD), cases refractory to typical DMARDs, Canakinumab (an anti-IL-1 β monoclonal antibody) has been reported to be effective in a limited number of refractory cases.¹

Objectives: The aim of this retrospective study was to represent AOSD patients treated with Canakinumab in 3 centres.

Methods: The follow up data of 10 AOSD patients (8 female, 2 male), who were followed up in outpatient clinics of 3 tertiary centres were reviewed retrospectively. The initial characteristics and follow up findings were reported.

Results: The mean timespan between the initial diagnosis and Canakinumab treatment 45.2 $\pm$ 29 months (mean $\pm$ SD). Before the onset of Canakinumab therapy, all patients were exposed to methotrexate, 1 to leflunomide, 8 to Tocilizumab and 8 to Anakinra. As for the biologic agents, 3 patients were also treated beforehand with Infliximab, 2 with Adalimumab, 2 with Etanercept and 2 with Rituximab. Canakinumab therapy was initiated in all patients with the indication of refractory disease under other medications, except for the one in whom neutropenia became evident under anakinra. The mean number of Canakinumab injections was 9.3 $\pm$ 8. The mean follow-up period of patients treated with Canakinumab was 43.1 $\pm$ 33 months. Seven out of 10 patients are still being treated with Canakinumab of 150 mg/month and one of 150 mg/every 2 months. One patient had a single injection and was fully controlled. The mean ferritin measure of 9 patients was reduced from 1292.3 $\pm$ 1530 ng/ml to 354 $\pm$ 530.2 ng/ml following the Canakinumab therapy (p=0.035). The mean of patient-reported global visual analogue scale (PG-VAS) scores was reduced from 7.4 $\pm$ 2.4 to 2.3 $\pm$ 2.2 with Canakinumab (p<0.001). Mean Erythrocyte sedimentation rate (ESR) was reduced from 44.2 $\pm$ 35.1 to 22.7 $\pm$ 26.5 with the help of Canakinumab therapy (p=0.005). Six patients are still on prednisolone at a maximum dose of 10 mg/day. The indication of therapy termination in the remaining 1 patient was the diagnosis of tuberculosis at 9th month of the treatment despite isoniazid prophylaxis. The patient was also treated with multiple biological agents beforehand, therefore it is not easy to conclude that treatment with Canakinumab induces tuberculosis flares.

Conclusions: Canakinumab treatment seems to be effective in refractory AOSD patients who were previously treated with various agents. We state that an IL-1 blocking agent, Canakinumab is a relatively safe and effective alternative in managing refractory AOSD cases. On the other hand, randomised controlled trials are needed to further investigate the role of Canakinumab in these cases as well as its use as the first choice of biologic agents.

REFERENCE:

- [1] Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1 β long-acting inhibitor, in refractory adult-onset Still's disease. *Semin Arthritis Rheum* 2012;42(2):201–5.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7187

THU0637 EVALUATIONS OF COMPLEMENT PATHWAYS IN IGG4 RELATED DISEASE

S. Fukui, Y. Fujita, T. Origuchi, A. Kawakami. *Immunology and Rheumatology, NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, Nagasaki, Japan*

Background: In IgG4 related disease (IgG4-RD), hypocomplementemia is known to be seen. Complement pathways consist of three pathways, classical,

alternative, and lectin pathways. Although IgG1 and IgG3 have ability to activate complement, IgG4 is known to be ineffective at activating complement.

Objectives: We attempted to elucidate which complement pathway is mainly associated with IgG4-RD.

Methods: Levels of complement elements and complement-associated elements, C1q, C2, C3, C3b/iC3b, C4, C4b, C5, C5a, C9, Factor D, Factor I, mannan-binding lectin (MBL), Factor B, Factor H, and properdin in preserved sera of patients with IgG4-RD at diagnosis and at remission were measured using multiplex bead-based assay. We compared complement levels at diagnosis of IgG4RD patients with those of sex-matched healthy donors.

Results: This study included 28 IgG4-RD patients and sex-matched 28 healthy donors. The median age at diagnosis and healthy donors' age were 65 [interquartile range (IQR): 55–70] and 64 (IQR:56–73), respectively. Patients with IgG4-RD at diagnosis had significantly higher levels of C5 and C5a [33347 ng/mL vs. 30375 ng/mL (median), p=0.0293, 16417 pg/mL vs. 7083 pg/mL, p<0.0001, respectively] and significantly lower levels of C4, C4b, and Factor D (219671 ng/mL vs. 325596 ng/mL, p=0.0140, 8784 ng/mL vs. 16285 ng/mL, p=0.0101, 4569 ng/mL vs. 5482 ng/mL, p=0.0299, respectively) compared to healthy donors. Levels of C5, C5a, C4, C4b, and Factor D were not different in two groups which were divided by clinical manifestations at diagnosis except for lower C4b levels in patients with lymphadenopathy compared with patients without lymphadenopathy. There were no differences in MBL, which was associated with the lectin pathway. In remission after the administrations of prednisolone, levels of C5a significantly decreased compared to levels of C5a at diagnosis (16305 pg/mL to 10029 pg/mL, p=0.0043). Other complement factors did not change significantly.

Conclusions: The classical complement pathway may be associated with IgG4-RD rather than the alternative pathway and the lectin pathway based on results except for Factor D.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5029

THU0638 CLINICAL CHARACTERISTIC OF A GROUP OF PATIENTS WITH PSTPIP1-ASSOCIATED MYELOID-RELATED PROTEINEMIA INFLAMMATORY SYNDROME (PAMI)

V.I. Burlakov¹, A. Kozlova¹, I. Mersyanova², A. Laberko¹, E. Viktorova¹, O. Shvets¹, D. Yukhacheva¹, G. Gordeeva¹, E. Raykina², V. Zakharova², J. Rodina¹, A. Shcherbina¹. ¹Immunology, National Medical Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia; ²Laboratory of Molecular Biology, National Medical Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russian Federation

Background: PSTPIP1-gene associated autoinflammatory diseases is a group of clinically diverse syndromes predominantly manifested by various skin conditions (pyoderma gangrenosum, acne, hidradenitis suppurativa, necrotizing fasciitis). Yet one of them – PAMI – manifests mainly with haematologic abnormalities and autoinflammation with or without purulent features, presenting diagnostic difficulties for treating physicians – mainly haematologists. PAMI treatment is also challenging as IL-1 inhibitors alleviate inflammatory symptoms but cytopenias usually require additional therapeutic agents.

Methods: We describe five PAMI patients from 3 families: (2 girls, 2 boys, and affected mother of two patients). c.748G>A(p.E250K) heterozygous mutation in PSTPIP1 was detected in all patients via targeted panel next generation sequencing and confirmed by Sanger sequencing.

Results: The median age of disease onset was 2 years (varied from at-birth onset to 7 years), the adult patient manifested at the age of 3. As described all patients manifested with cytopenias: thrombocytopenia in three, severe anaemia in five, neutropenia in three. All patients had elevated CRP and zinc levels, as previously described. Splenomegaly was noted in five, lymphadenopathy in one, colitis in one, severe arthritis in one (adult patient) and arthropathy in two patients. Mild pyoderma was noted only in one patient, two patients had skin vasculitis. One patient developed myelodysplastic syndrome and underwent successful hematopoietic stem cell transplantation (HSCT).

All patients received various immunosuppression prior to diagnosis with partial effect. After PAMI diagnosis rituximab was effective in two out of three, tocilizumab in one out of two, high dose anakinra in one patient. The girl who underwent HSCT is currently well, with full donor chimerism.

Conclusions: Haematologists need to be aware of the PAMI phenotype and include it in the diagnostic algorithm. Treatment still remains challenging and requires further investigation in larger groups of patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7244